Thomas E Ichim博士

Thomas E Ichim博士，美国免疫学和干细胞专家，2005年获多伦多大学免疫学博士学位，毕业后从事干细胞研发工作。2007年创建干细胞公司Medistem, 研发的ERC干细胞获得美国FDA批准用于临床试验治疗肢端缺陷和心衰。 2014年Medistem被上市公司Intrexon收购。在干细胞领域享有盛名，发表论文98篇， 获得美国专利34个。

MAJOR ACCOMPLISHMENTS/RESPONSIBILITIES:

At Immune Advisors

Initiated, grew, and manages stock positions in 5 biotech companies

Batu Biologics, Cancer Vaccine Company; Raised $2.2 million, initiated clinical trialso Nobilis Therapeutics, Psychiatric Company; Raised $500,000, Harvard Licensed Drug, to enter clinic in Q3 2017

Creative Medical Technology Holdings; Entered clinical trials in 2017, publicly listed (Ticker CELZ)

Therapeutics Solutions International (Ticker TSOI), cancer fighting nutritional supplements, issued patent

Immunicom, private cancer immunotherapy company developing extracorporeal devices to remove tumor secreted blocking factors from circulation

AngioStem, private stem cell company working in treatment of neonatal ischemia reperfusion

Viera BioSciences, private immunotherapy company using immune modulation for unmet medical needs.

At Medistem:

• Discovered a new stem cell that is economical to manufacture and is non-embryonic

• Obtained FDA approval for testing stem cell in patients (clinical trials)

• Recruited internationally-renowned doctors (Mike Murphy Indiana University, first to use stem cells for leg conditions in USA and Amit Patel University of Utah, first to use stem cells in human heart in world) to perform the trials

• Inventing 20 families of patents and patent applications in area of regenerative medicine

• Recruiting former CEO of Juvenile Diabetes Research Foundation, Alan Lewis, to become Medistem CEO

• Initiated and led collaborations with biotechnology companies (Benitec Biopharma,Aethlon Medical, Entest Biomedical, Orcrist Bio) leading to scientific publications and Federal SBIR grant

• Initiated and led collaborations with international universities including: University of Utah; University of California San Diego; Indiana University; National Institutes of Health; Central South University, Changsha, China; Regenerative Medicine and Cell Therapies Laboratory, CUCAIBA, Ministry of Health Argentina; University of Western Ontario; University of Alberta; Institute for Molecular Medicine; Karelian Research Center, Russian Academy of Sciences, Petrozavodsk, Russia;

• Recruited Medistem’s Advisory Board including Dr. Hugh Taylor, Director of Reproductive Biology at Yale University, and Dr Gene Ray, founder and CEO of Titan which had a 2.6 Billion liquity event

• Published 67 peer reviewed scientific publications with Medistem

• Sold Company to NYSE Traded Company, Intrexon, for 26 Million Dollars At Regen BioPharma:

• Assembled clinical development program with FDA application in preparation for treatment of aplastic anemia

• Invented 2 patents for treatment of bone marrow disorders

• One peer reviewed manuscript accepted for publication

• Obtained IND for treatment of Aplastic Anemia using Adipose Stem Cells At OncoMune:

• Obtained issued patent # 8,263,571 covering means of treating cancer by blocking new cancer-causing gene

• Developed preclinical and clinical strategy, including 1 peer reviewed publication At bioRASI:

• Designed and executed clinical trials for assessing efficacy of novel interventions in human subjects with specialization in stem cells/regenerative medicine

• Assisted clients in publishing and patenting data At Vendevia:

• Performed scientific due diligence before investment/partnerships

• Designed scientific/clinical development plan for portfolio companies

• Worked with the Chief Scientific Officer to develop overall technology strategy for the fund At Dept Surgery, University of Western Ontario (Weiping Min Lab):

• Laboratory research involving cell therapy and transplantation

• Filed patents on first use of RNA interference for immune modulation

• Published scientific papers and assisted in grant writing At MedVax Pharma Corp:

• Invented new cancer vaccine and filed patent application

• Published peer-reviewed proof of concept manuscriptAt ToleroTech:

• Invented new uses of RNA interference for organ transplant rejection

• Demonstrated proof-of-concept in animal models and published in peer reviewed journals

• Obtained Proof of Principle grant for Wei-Ping Min’s laboratory At Marrowtech Pharma:

• Compiled preclinical data and filed successful application to perform clinical trials using stem cell generated cancer inhibitor At Department of Microbiology and Immunology, University of Western Ontario:

• Performed laboratory experiments using stem cell generated cancer inhibitor At Batu Center for Leukemia Research:

• Developed proposal for new stem cell based method of treating leukemia in collaboration with Dr. Mark Minden

• Organized and executed national fundraising campaign to fund leukemia research At University of Guelph

• Designed and executed research project assessing effects of antioxidants on porcine lymphocyte proliferation

• Presented results at the 4th International Veterinary Immunology Symposium, Davis California